A Study To Test An Anti-Rejection Therapy After Kidney Transplantation
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of May 09, 2025
Terminated
Keywords
ClinConnect Summary
Renal transplantation is recognized as the treatment of choice for children with chronic renal failure. However, patient and graft survival rates in young children are unacceptably low. In preliminary studies, OKT3 (a monoclonal antibody) induction therapy received post transplant has been more successful than standard immunosuppression alone in improving graft survival. This study is designed to assess the impact of induction therapy on graft survival in pediatric kidney transplant patients.
Patients are assigned to OKT3 induction or no induction in a 1:1 ratio. Randomization to oral cycl...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Children and young adults may be eligible for this study if they:
- • Are not yet 21 years of age.
- • Are receiving their first or second transplant.
- • Are not pregnant.
- • Agree to practice sexual abstinence or agree to use an effective
- • method of birth control/contraception during the study and
- • for 1 year after.
- • Exclusion Criteria
- Children and young adults will not be eligible for this study if they:
- • Are recipients of multiple organs other than kidneys.
- • Are recipients of three or more transplants.
- • Are HIV positive.
- • Are Hepatitis B surface antigen positive.
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rockville, Maryland, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials